Irinotecan/oxaliplatin: Dysarthria and speech disturbances: 2 case reports

In a case series, a 38-year-old man developed dysarthria and speech disturbances during treatment with irinotecan and oxaliplatin and a 54-year-old woman developed dysarthria following treatment with oxaliplatin and irinotecan.

Case 1: A 38-year-old man, who had pancreatic cancer, was scheduled to receive FOLFIRINOX regimen comprising irinotecan infusion 180 mg/m², oxaliplatin infusion 85 mg/m², folinic acid [leucovorin] and fluorouracil. Two hours after infusion of oxaliplatin and just after initiation of irinotecan infusion, he developed dysarthria. Two...